1 Followers USX:IMAB - I-Mab I-Mab
Sector: Health Care, Industry: Biotechnology
Add to Watchlist
   
Add Alert 


Yahoo Finance

USD 70.3    -6.270 (-8.19%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

23 Sep 2021


Loading...
Loading...
Loading...

General

CEO: Dr. Jingwu Zhang Zang M.D., Ph.D.

IPO: 2020-01-17

Headquarters: US

Employees: 228

Homepage

Description

I-MAB Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia.